Evidence map›Paper›PMID 41312368›Full record

ArticleFrontiers in immunology2025

Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

Walther Brochier, Sylvain Nguyen, Valérie Cesson, Orian Bricard, Nicolas van Baren, Gérald Hames, Nicolas Dauguet, Hélène Dano, Bertrand Tombal, Sonia-Cristina Rodrigues-Dias and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Walther Brochier *de Duve Institute, UCLouvain, Brussels, Belgium.
Sylvain Nguyen *Urology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Valérie CessonUrology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Orian Bricardde Duve Institute, UCLouvain, Brussels, Belgium.
Nicolas van Barende Duve Institute, UCLouvain, Brussels, Belgium.
Gérald Hamesde Duve Institute, UCLouvain, Brussels, Belgium.
Nicolas Dauguetde Duve Institute, UCLouvain, Brussels, Belgium.
Hélène DanoDepartment of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Bertrand TombalDepartment of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Sonia-Cristina Rodrigues-DiasUrology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Audrey MasnadaUrology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Raphael GenoletLudwig Institute for Cancer Research, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Alexandre HarariLudwig Institute for Cancer Research, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Beat RothDepartment of Urology, University Hospital of Bern, Inselspital, University of Bern, Bern, Switzerland.
Ilaria LuccaUrology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Denise Nardelli-HaefligerUrology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.
Pierre G Coulie *de Duve Institute, UCLouvain, Brussels, Belgium.
Laurent Derré *Urology Research Unit and Urology Biobank, Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bladder carcinomas are immunogenic, and patients with bladder cancer benefit from immune checkpoint therapy. This is correlated to a high tumor mutation burden, which provides a higher number of neoepitopes that can be recognized by tumor-specific CD8 Methods: In a first cohort of 15 NMIBC and 9 muscle invasive bladder cancer patients, we used IFN- Results: 9 out of 24 patients from the first cohort mounted a spontaneous and functional anti-neoepitope T-cell response in blood and/or tumor. In 5 patients from this cohort who were treated with BCG, no neoantigen-specific T cells were detected in urine during treatment. In the second cohort, 6 out of 6 TCRs from exhausted CD8 Conclusions: We show that one third of patients with non-metastatic bladder cancer mount a spontaneous and functional anti-neoepitope CD8

Indexed as

CD8-Positive T-LymphocytesEpitopes, T-LymphocyteLymphocytes, Tumor-InfiltratingUrinary Bladder NeoplasmsAgedAged, 80 and overAntigens, NeoplasmBCG VaccineFemaleHumansMaleMiddle AgedAntigens, NeoplasmBCG VaccineEpitopes, T-LymphocyteBCG treatmentbladder cancerimmunotherapyneoepitopeT lymphocyte

Identifiers

PMID41312368
PMCPMC12648094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.